Literature DB >> 21359970

ECT in a patient with Parkinson's disease and schizophrenia, with dopamine transporter visualisation using 123I-ioflupane SPET.

Paloma Fernández-Corcuera1, Salvatore Aguilar, Víctor Viçens, Jaume Mora, Ana Benitez, Amparo García-Burillo, Edith Pomarol-Clotet, Peter McKenna.   

Abstract

A 58-year old woman with chronic schizophrenia developed worsening parkinsonian symptoms over the previous 6 years, and was eventually diagnosed as having Parkinson's disease. Antipsychotics were stopped because they worsened these symptoms. Antiparkinsonian treatment led to a significant increase in delusions and behavioural disorganisation. The patient underwent electroconvulsive-therapy which improved both her psychiatric and motor symptoms. After treatment, 123I-Ioflupane uptake was mildly increased in the left caudate nucleus, but uptake in right caudate nucleus was lower than in a pretreatment scan.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21359970     DOI： 10.1007/s00702-011-0615-8

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN： 0300-9564            Impact factor:   3.575


  21 in total

1.  Increased striatal dopamine transporter levels, as indicated by a DAT scan, induced by ziprasidone in association to improvement of tardive dyskinesia--a case report.

Authors:  E N Rizos; S Chatziioannou; N Siafakas; A Douzenis; E Katsantoni; A Mandrapilia; S Bacalis; C Fotiadis; L Lykouras
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2010-05-10       Impact factor: 5.067

2.  Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait.

Authors:  Jose J Mateos; Francisco Lomeña; Eduard Parellada; Font Mireia; Emili Fernandez-Egea; Javier Pavia; Alberto Prats; Francisca Pons; Miquel Bernardo
Journal:  Psychopharmacology (Berl)       Date:  2006-09-22       Impact factor: 4.530

3.  A double-blind evaluation of electroconvulsive therapy in Parkinson's disease with "on-off" phenomena.

Authors:  K Andersen; J Balldin; C G Gottfries; A K Granérus; K Modigh; L Svennerholm; A Wallin
Journal:  Acta Neurol Scand       Date:  1987-09       Impact factor: 3.209

Review 4.  Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder.

Authors:  C Mehler-Wex; P Riederer; M Gerlach
Journal:  Neurotox Res       Date:  2006-12       Impact factor: 3.911

Review 5.  Neuropsychiatric considerations in the use of electroconvulsive therapy.

Authors:  A D Krystal; C E Coffey
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1997       Impact factor: 2.198

6.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

7.  D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia.

Authors:  Monte S Buchsbaum; Bradley T Christian; Douglas S Lehrer; Tanjore K Narayanan; Bingzhi Shi; Joseph Mantil; Eileen Kemether; Terrence R Oakes; Jogeshwar Mukherjee
Journal:  Schizophr Res       Date:  2006-05-19       Impact factor: 4.939

8.  Effects of the D3 and autoreceptor-preferring dopamine antagonist (+)-UH232 in schizophrenia.

Authors:  A C Lahti; M Weiler; A Carlsson; C A Tamminga
Journal:  J Neural Transm (Vienna)       Date:  1998       Impact factor: 3.575

9.  [Diagnostic accuracy of FP-CIT SPECT in patients with parkinsonism].

Authors:  S J Ortega Lozano; M D Martínez Del Valle Torres; J M Jiménez-Hoyuela García; A L Gutiérrez Cardo; V Campos Arillo
Journal:  Rev Esp Med Nucl       Date:  2007 Sep-Oct

10.  Signs of striatal dopamine transporter density increase in association with improvement of tardive dyskinesia in a patient with schizophrenia, as demonstrated by a DAT scan.

Authors:  E N Rizos; S Chatziioannou; A Douzenis; N Siafakas; E Katsantoni; P Nikolaidou; M Papathanasiou; L Lykouras
Journal:  Eur Neuropsychopharmacol       Date:  2009-09-08       Impact factor: 4.600
View more
  5 in total

1.  Elevated dopamine D1 receptor availability in striatum of Göttingen minipigs after electroconvulsive therapy.

Authors:  Anne M Landau; Aage Ko Alstrup; Helene Audrain; Steen Jakobsen; Mette Simonsen; Arne Møller; Poul Videbech; Gregers Wegener; Albert Gjedde; Doris J Doudet
Journal:  J Cereb Blood Flow Metab       Date:  2017-05-16       Impact factor: 6.200

2.  Antidepressant treatment effects on dopamine transporter availability in patients with major depression: a prospective 123I-FP-CIT SPECT imaging genetic study.

Authors:  Sabine Hellwig; Lars Frings; Annette Masuch; Werner Vach; Katharina Domschke; Claus Normann; Philipp T Meyer
Journal:  J Neural Transm (Vienna)       Date:  2018-02-23       Impact factor: 3.575

3.  Evaluation of Serum Apolipoprotein E as a Potential Biomarker for Pharmacological Therapeutic Efficacy Monitoring in Dopamine Dictated Disease Spectrum of Schizophrenia and Parkinson's disease: A Preliminary Study.

Authors:  Ashish Kumar Gupta; Komal Rani; Surabhi Swarnkar; Gaurav Khunger Kumar; Mohd Imran Khan; Ruchika Pokhriyal; Domada Ratna Kumar; Vinay Goyal; Manjari Tripathi; Rishab Gupta; Rakesh Kumar Chadda; Perumal Vanamail; Gururao Hariprasad
Journal:  J Cent Nerv Syst Dis       Date:  2018-10-09

4.  2D-DIGE as a strategy to identify serum protein biomarkers to monitor pharmacological efficacy in dopamine-dictated states of Parkinson's disease and schizophrenia.

Authors:  Ashish Kumar Gupta; Gaurav Khunger Kumar; Komal Rani; Ruchika Pokhriyal; Mohd Imran Khan; Domada Ratna Kumar; Vinay Goyal; Manjari Tripathi; Rishab Gupta; Rakesh Kumar Chadda; Perumal Vanamail; Ashok Kumar Mohanty; Gururao Hariprasad
Journal:  Neuropsychiatr Dis Treat       Date:  2019-04-24       Impact factor: 2.570

5.  Cerebrospinal Fluid Proteomics For Identification Of α2-Macroglobulin As A Potential Biomarker To Monitor Pharmacological Therapeutic Efficacy In Dopamine Dictated Disease States Of Parkinson's Disease And Schizophrenia.

Authors:  Ashish Kumar Gupta; Ruchika Pokhriyal; Mohd Imran Khan; Domada Ratna Kumar; Rishab Gupta; Rakesh Kumar Chadda; Rashmi Ramachandran; Vinay Goyal; Manjari Tripathi; Gururao Hariprasad
Journal:  Neuropsychiatr Dis Treat       Date:  2019-10-02       Impact factor: 2.570
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.